Anyone Know HOW This Work’s

Turning NEGATVES into positives with immutherpy drugs.

Tremelimumab STORY is quite interesting.

Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy with limited therapeutic options and poor

prognosis. There has been long-standing interest in the potential applications of immunotherapy for the treatment of MPM. Recently, B7-H1, also known as programmed cell death ligand 1, expression in MPM was correlated with sarcomatoid subtypes and worse clinical outcomes (1). In addition, a recent clinical trial suggested a potential role for cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibition for the treatment of MPM (2). These studies suggest MPM may be sensitive to immune checkpoint inhibitors.

Here we present the case of a patient with spontaneous regression of MPM in the setting of the onset of an autoimmune syndrome. atsjournals.org/doi/pdf/10....

[RoyCastleHelpline Partner Ask the Nurse Roy Castle]

Hi JefffAjaxSmith,

You may find the following link interesting. The commentary considers the characteristic features and biology of MPM and the challenges in its clinical management. It includes key ongoing clinical trials and emerging therapies as well as an experts view on how treatment of malignant pleural mesothelioma may change in the next 5 years.

Available: inoncology.com/tumour-types...

Regards,

All the team at the Roy Castle Helpline

[Hidden in reply to RoyCastleHelpline]

Hi cheers thanks for information resource very interesting informative.

Not gone right through it tho BUT appreciate link feed back